Teledyne FLIR Announces ION M640x Next-Gen Tactical Quadcopter
11.10.2021 14:01:00 EEST | Business Wire | Press release
Teledyne FLIR, part of Teledyne Technologies Incorporated (NYSE:TDY), today announced the launch of the ION™ M640x tactical Unmanned Aerial System (UAS). The American designed, developed, and manufactured UAS builds on the capabilities of the ION M440 (a Blue sUAS) and will provide military and other government customers with best-in-class capabilities for their unique missions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211011005025/en/
The Teledyne FLIR ION™ M640x tactical Unmanned Aerial System (UAS) is an American designed, developed, and manufactured UAS that will provide military and public safety users with best-in-class capabilities for their missions. The ION M640x features a 640x512 infrared sensor providing twice the resolution of similar UAS, and a Near-Infrared (NIR) laser illuminator. ION M640x includes all-new smart object tracking that enables operators to designate an object for the aircraft to detect and track while it moves. The M640x is MAVLINK compliant and interoperable with Common Ground Control Stations (C-GCS), including the U.S. Army Tactical Open Ground Station Architecture (TOGA). Easily rucksack portable at about 4 pounds, the M640x is rated for operation in demanding environments, including rain and wind. The ION M640x is evolved from the ION M440, one of the original five UAS platforms approved by the U.S. Dept. of Defense under the Blue sUAS program. (Photo: Business Wire)
“Our proven, U.S.-based engineering expertise and focus on defense and public safety markets means our customers are getting the most secure and capable UAS solutions,” said Thomas Rambo, senior director of Unmanned and Integrated Solutions at Teledyne FLIR. “The ION M640x builds on our unique position as a domestic provider of unmanned systems and sensing technology and boasts high resolution infrared imaging, smart object tracking, laser illumination, and industry-leading support and service.”
The ION M640x features a 640x512 infrared sensor providing twice the resolution of similar UAS, and a Near-Infrared (NIR) laser illuminator. The NIR illuminator enables operators to pinpoint objects of interest for increased coordination and visibility for other mission participants. ION M640x also includes all-new smart object tracking that enables operators to designate an object for the aircraft to detect and track while it moves. Other new features include an SD card to easily retrieve photos and video recorded during flight, as well as tri-band radio capabilities.
Open system architecture is another key feature of the ION M640x, and the system utilizes a high-powered discrete mission computer for advanced autonomous functions. It is also MAVLINK compliant and interoperable with Common Ground Control Stations (C-GCS), including the U.S. Army Tactical Open Ground Station Architecture (TOGA). Easily rucksack portable at about 4 pounds, the M640x is rated for operation in demanding environments, including rain and wind.
The ION M640x is evolved from the ION M440, one of the original five UAS platforms approved by the U.S. Department of Defense under the Blue sUAS program, for sale to U.S. military and federal agencies. The M440 was developed by Gainesville, Florida-based Altavian Inc., which FLIR acquired in December 2020.
Leveraging Teledyne FLIR’s longstanding reputation as a trusted provider of unmanned systems for military and public safety organizations, the ION M640x is backed by the company’s world class standards for service, training, and technical support.
About Teledyne FLIR
Teledyne FLIR, a Teledyne Technologies company, is a world leader in intelligent sensing solutions for defense and industrial applications with approximately 4,000 employees worldwide. Founded in 1978, the company creates advanced technologies to help professionals make better, faster decisions that save lives and livelihoods. For more information, please visit www.teledyneflir.com or follow @flir.
About Teledyne Technologies
Teledyne Technologies is a leading provider of sophisticated digital imaging products and software, instrumentation, aerospace and defense electronics, and engineered systems. Teledyne's operations are primarily located in the United States, the United Kingdom, Canada, and Western and Northern Europe. For more information, visit Teledyne's website at www.teledyne.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005025/en/
Contact information
Joe Ailinger, Jr.
Teledyne FLIR
Phone: +1 781-801-6161
Email: joe.ailinger@teledyneflir.com
Ryan Williams
Targeted Victory
Phone: +1 617-697-9072
Email: rwilliams@targetedvictory.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN ® APN6.8.2026 07:30:00 EEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom